cbdMD Inc (NYSE American: YCBD) is a consumer wellness company that develops and sells hemp-derived CBD and cannabinoid products under multiple brands. Revenue comes from direct-to-consumer e-commerce and traditional retail distribution, with total net sales of $19.2 million in fiscal year ended September 2025 and $19.5 million in fiscal year ended September 2024. The company operates brands including cbdMD, Paw CBD, ATRx Labs, and Oasis, the last being a hemp-derived THC beverage line launched in the first quarter of fiscal 2025. Gross margin was 63.0% in FY2025, up from 61.6% in FY2024, while operating loss narrowed from $3.3 million to $2.1 million over the same period. The company carries 1.7 million shares of Series B Convertible Preferred Stock outstanding as of the December 2025 filing date, pays no common stock dividend, and regained NYSE American listing compliance in fiscal 2025 after converting Series A Convertible Preferred Stock into approximately 91% of outstanding common shares.
Source: SEC 10-K, filed 2025-12-19
Industry: Perfumes, Cosmetics & Other Toilet Preparations Peers: Ampio Pharmaceuticals, Inc. TREX WIND-DOWN, INC. PLx Pharma Winddown Corp. Eloxx Pharmaceuticals Inc Evofem Biosciences Inc Jaguar Health Inc Johnson & Johnson Vyne Therapeutics Inc Unrivaled Brands, Inc. Virpax Pharmaceuticals, Inc.
Loading...